Dataset Viewer
Auto-converted to Parquet Duplicate
registry_id
stringlengths
17
17
year
int64
2.02k
2.02k
age
int64
0
94
age_group
stringclasses
8 values
sex
stringclasses
2 values
cancer_type
stringclasses
15 values
morphology
stringclasses
7 values
grade
stringclasses
5 values
basis_of_diagnosis
stringclasses
4 values
vital_status
stringclasses
3 values
survival_months
float64
0
369
scenario
stringclasses
1 value
RW-KGL-2019-00001
2,019
6
0-14
Male
Other
Squamous cell carcinoma
Grade IV
Microscopy
Alive
37.8
moderate_burden
RW-KGL-2021-00002
2,021
40
35-44
Male
Colorectum
Squamous cell carcinoma
Grade II
DCO
Dead
14.9
moderate_burden
RW-KGL-2021-00003
2,021
75
75+
Female
Other
Squamous cell carcinoma
Grade IV
Microscopy
Alive
56
moderate_burden
RW-KGL-2015-00004
2,015
45
45-54
Female
Cervix uteri
Adenocarcinoma
Grade III
Microscopy
Alive
13.2
moderate_burden
RW-KGL-2019-00005
2,019
57
55-64
Male
Kaposi sarcoma
Lymphoma
Grade II
Microscopy
Alive
47.2
moderate_burden
RW-KGL-2016-00006
2,016
69
65-74
Male
Colorectum
Sarcoma
Grade IV
Imaging + clinical
Dead
27
moderate_burden
RW-KGL-2015-00007
2,015
52
45-54
Female
Breast
Lymphoma
Grade III
Microscopy
Alive
45.4
moderate_burden
RW-KGL-2019-00008
2,019
72
65-74
Female
Ovary
Sarcoma
Grade II
Microscopy
Alive
13.1
moderate_burden
RW-KGL-2020-00009
2,020
53
45-54
Female
Ovary
Squamous cell carcinoma
Unknown
Microscopy
Dead
26.8
moderate_burden
RW-KGL-2021-00010
2,021
41
35-44
Female
Thyroid
Non-keratinizing
Grade II
Clinical only
Lost
37
moderate_burden
RW-KGL-2016-00011
2,016
73
65-74
Male
Other
Adenocarcinoma
Grade II
Microscopy
Dead
62
moderate_burden
RW-KGL-2021-00012
2,021
49
45-54
Female
Other
Sarcoma
Grade III
Imaging + clinical
Dead
5.8
moderate_burden
RW-KGL-2021-00013
2,021
50
45-54
Female
Other
Sarcoma
Grade II
Microscopy
Alive
0.6
moderate_burden
RW-KGL-2020-00014
2,020
33
25-34
Male
Colorectum
Sarcoma
Grade I
Microscopy
Lost
29.3
moderate_burden
RW-KGL-2016-00015
2,016
27
25-34
Female
Breast
Squamous cell carcinoma
Grade I
Imaging + clinical
Alive
15.3
moderate_burden
RW-KGL-2020-00016
2,020
72
65-74
Female
Other
Other
Grade II
Microscopy
Dead
93.6
moderate_burden
RW-KGL-2016-00017
2,016
46
45-54
Male
Non-Hodgkin lymphoma
Other
Grade II
Microscopy
Alive
32.7
moderate_burden
RW-KGL-2020-00018
2,020
45
45-54
Female
Other
Adenocarcinoma
Grade I
Microscopy
Alive
10.4
moderate_burden
RW-KGL-2017-00019
2,017
58
55-64
Male
Other
Lymphoma
Unknown
Microscopy
Alive
76.6
moderate_burden
RW-KGL-2019-00020
2,019
60
55-64
Female
Cervix uteri
Lymphoma
Grade III
Microscopy
Dead
21.8
moderate_burden
RW-KGL-2018-00021
2,018
57
55-64
Male
Other
Squamous cell carcinoma
Grade III
Microscopy
Alive
15.1
moderate_burden
RW-KGL-2020-00022
2,020
58
55-64
Female
Cervix uteri
Squamous cell carcinoma
Grade IV
Microscopy
Dead
20.4
moderate_burden
RW-KGL-2021-00023
2,021
48
45-54
Male
Prostate
Squamous cell carcinoma
Grade III
Microscopy
Alive
32.6
moderate_burden
RW-KGL-2020-00024
2,020
67
65-74
Female
Cervix uteri
Squamous cell carcinoma
Grade II
Microscopy
Alive
20.8
moderate_burden
RW-KGL-2018-00025
2,018
40
35-44
Female
Other
Squamous cell carcinoma
Grade III
Microscopy
Dead
2.5
moderate_burden
RW-KGL-2016-00026
2,016
58
55-64
Female
Cervix uteri
Squamous cell carcinoma
Grade II
Microscopy
Lost
19
moderate_burden
RW-KGL-2021-00027
2,021
63
55-64
Male
Kaposi sarcoma
Adenocarcinoma
Grade II
Microscopy
Dead
21.6
moderate_burden
RW-KGL-2017-00028
2,017
38
35-44
Male
Prostate
Non-keratinizing
Unknown
Microscopy
Alive
4.5
moderate_burden
RW-KGL-2018-00029
2,018
37
35-44
Female
Breast
Leukemia
Grade I
Microscopy
Lost
22
moderate_burden
RW-KGL-2020-00030
2,020
53
45-54
Female
Ovary
Non-keratinizing
Grade III
Microscopy
Lost
4.4
moderate_burden
RW-KGL-2019-00031
2,019
46
45-54
Female
Other
Leukemia
Grade III
Microscopy
Dead
4.6
moderate_burden
RW-KGL-2019-00032
2,019
65
65-74
Female
Breast
Sarcoma
Grade III
Microscopy
Alive
25.8
moderate_burden
RW-KGL-2016-00033
2,016
50
45-54
Male
Stomach
Sarcoma
Grade II
Microscopy
Alive
88.1
moderate_burden
RW-KGL-2016-00034
2,016
23
15-24
Female
Breast
Non-keratinizing
Grade II
Microscopy
Dead
1.3
moderate_burden
RW-KGL-2020-00035
2,020
31
25-34
Female
Cervix uteri
Squamous cell carcinoma
Grade II
Clinical only
Dead
35.5
moderate_burden
RW-KGL-2020-00036
2,020
72
65-74
Female
Breast
Sarcoma
Grade II
Microscopy
Alive
16.3
moderate_burden
RW-KGL-2016-00037
2,016
35
35-44
Male
Kaposi sarcoma
Adenocarcinoma
Grade IV
Imaging + clinical
Dead
135.9
moderate_burden
RW-KGL-2015-00038
2,015
38
35-44
Female
Other
Adenocarcinoma
Grade II
Clinical only
Alive
0.4
moderate_burden
RW-KGL-2021-00039
2,021
46
45-54
Female
Other
Lymphoma
Grade II
Microscopy
Alive
33.7
moderate_burden
RW-KGL-2017-00040
2,017
63
55-64
Male
Other
Lymphoma
Grade I
Microscopy
Alive
7.7
moderate_burden
RW-KGL-2015-00041
2,015
36
35-44
Female
Cervix uteri
Adenocarcinoma
Grade II
Microscopy
Alive
11
moderate_burden
RW-KGL-2018-00042
2,018
60
55-64
Female
Other
Squamous cell carcinoma
Grade I
Microscopy
Dead
11.4
moderate_burden
RW-KGL-2018-00043
2,018
52
45-54
Female
Other
Adenocarcinoma
Grade I
Microscopy
Alive
18.8
moderate_burden
RW-KGL-2021-00044
2,021
40
35-44
Female
Cervix uteri
Non-keratinizing
Grade I
Microscopy
Alive
52.2
moderate_burden
RW-KGL-2017-00045
2,017
32
25-34
Female
Cervix uteri
Sarcoma
Grade II
Imaging + clinical
Dead
1.1
moderate_burden
RW-KGL-2017-00046
2,017
51
45-54
Male
Other
Squamous cell carcinoma
Grade II
Microscopy
Alive
33.8
moderate_burden
RW-KGL-2021-00047
2,021
36
35-44
Female
Breast
Non-keratinizing
Grade I
Microscopy
Alive
31.4
moderate_burden
RW-KGL-2015-00048
2,015
47
45-54
Female
Other
Adenocarcinoma
Grade III
Microscopy
Dead
45.8
moderate_burden
RW-KGL-2019-00049
2,019
73
65-74
Female
Other
Squamous cell carcinoma
Grade II
Microscopy
Alive
10.5
moderate_burden
RW-KGL-2019-00050
2,019
61
55-64
Female
Breast
Squamous cell carcinoma
Unknown
Imaging + clinical
Alive
59.5
moderate_burden
RW-KGL-2017-00051
2,017
59
55-64
Female
Breast
Squamous cell carcinoma
Grade III
Microscopy
Alive
9.5
moderate_burden
RW-KGL-2019-00052
2,019
37
35-44
Female
Other
Lymphoma
Grade III
Imaging + clinical
Dead
26.7
moderate_burden
RW-KGL-2019-00053
2,019
26
25-34
Male
Hodgkin lymphoma
Lymphoma
Grade III
Clinical only
Dead
4
moderate_burden
RW-KGL-2019-00054
2,019
47
45-54
Male
Liver
Sarcoma
Grade II
Microscopy
Dead
8.9
moderate_burden
RW-KGL-2020-00055
2,020
36
35-44
Male
Prostate
Sarcoma
Unknown
Imaging + clinical
Dead
21.5
moderate_burden
RW-KGL-2021-00056
2,021
63
55-64
Female
Breast
Squamous cell carcinoma
Grade III
DCO
Dead
25
moderate_burden
RW-KGL-2019-00057
2,019
41
35-44
Female
Breast
Adenocarcinoma
Grade I
Imaging + clinical
Dead
105.6
moderate_burden
RW-KGL-2017-00058
2,017
60
55-64
Female
Cervix uteri
Adenocarcinoma
Grade III
Imaging + clinical
Alive
6.4
moderate_burden
RW-KGL-2017-00059
2,017
51
45-54
Male
Kaposi sarcoma
Non-keratinizing
Grade II
Clinical only
Alive
49.2
moderate_burden
RW-KGL-2020-00060
2,020
58
55-64
Female
Other
Squamous cell carcinoma
Unknown
Clinical only
Alive
6.4
moderate_burden
RW-KGL-2019-00061
2,019
48
45-54
Male
Colorectum
Adenocarcinoma
Grade IV
Clinical only
Lost
2.5
moderate_burden
RW-KGL-2019-00062
2,019
25
25-34
Female
Breast
Sarcoma
Grade III
Microscopy
Dead
9.6
moderate_burden
RW-KGL-2020-00063
2,020
67
65-74
Male
Prostate
Sarcoma
Grade I
Microscopy
Dead
4.1
moderate_burden
RW-KGL-2021-00064
2,021
61
55-64
Male
Kaposi sarcoma
Adenocarcinoma
Grade IV
Microscopy
Dead
7.1
moderate_burden
RW-KGL-2015-00065
2,015
68
65-74
Female
Breast
Adenocarcinoma
Grade II
Imaging + clinical
Alive
15.6
moderate_burden
RW-KGL-2017-00066
2,017
57
55-64
Female
Cervix uteri
Sarcoma
Grade II
Microscopy
Alive
5.1
moderate_burden
RW-KGL-2019-00067
2,019
57
55-64
Female
Cervix uteri
Squamous cell carcinoma
Grade I
Imaging + clinical
Dead
54
moderate_burden
RW-KGL-2017-00068
2,017
31
25-34
Female
Breast
Squamous cell carcinoma
Grade III
DCO
Alive
43.2
moderate_burden
RW-KGL-2021-00069
2,021
63
55-64
Female
Thyroid
Non-keratinizing
Grade II
Microscopy
Alive
25.1
moderate_burden
RW-KGL-2017-00070
2,017
55
55-64
Female
Other
Other
Grade IV
DCO
Alive
8.3
moderate_burden
RW-KGL-2018-00071
2,018
67
65-74
Female
Cervix uteri
Non-keratinizing
Grade III
Microscopy
Alive
13.4
moderate_burden
RW-KGL-2017-00072
2,017
39
35-44
Female
Breast
Adenocarcinoma
Grade IV
Microscopy
Alive
31.3
moderate_burden
RW-KGL-2020-00073
2,020
68
65-74
Male
Colorectum
Leukemia
Grade IV
Microscopy
Dead
8.3
moderate_burden
RW-KGL-2017-00074
2,017
56
55-64
Female
Breast
Non-keratinizing
Grade III
Microscopy
Dead
7.5
moderate_burden
RW-KGL-2016-00075
2,016
37
35-44
Female
Breast
Sarcoma
Grade I
Microscopy
Dead
55.7
moderate_burden
RW-KGL-2016-00076
2,016
27
25-34
Female
Cervix uteri
Lymphoma
Grade II
Imaging + clinical
Dead
13.9
moderate_burden
RW-KGL-2017-00077
2,017
62
55-64
Male
Other
Adenocarcinoma
Unknown
Clinical only
Lost
9
moderate_burden
RW-KGL-2018-00078
2,018
43
35-44
Female
Other
Squamous cell carcinoma
Grade II
DCO
Alive
24.3
moderate_burden
RW-KGL-2017-00079
2,017
56
55-64
Male
Non-Hodgkin lymphoma
Sarcoma
Unknown
DCO
Dead
79.6
moderate_burden
RW-KGL-2018-00080
2,018
16
15-24
Male
Non-Hodgkin lymphoma
Squamous cell carcinoma
Grade I
DCO
Lost
15.2
moderate_burden
RW-KGL-2020-00081
2,020
46
45-54
Male
Hodgkin lymphoma
Sarcoma
Grade III
Microscopy
Dead
2.3
moderate_burden
RW-KGL-2016-00082
2,016
42
35-44
Female
Cervix uteri
Non-keratinizing
Grade I
Microscopy
Alive
2.8
moderate_burden
RW-KGL-2018-00083
2,018
16
15-24
Female
Cervix uteri
Lymphoma
Grade III
DCO
Alive
11.7
moderate_burden
RW-KGL-2020-00084
2,020
50
45-54
Female
Breast
Sarcoma
Grade I
Microscopy
Dead
1.7
moderate_burden
RW-KGL-2019-00085
2,019
51
45-54
Male
Stomach
Sarcoma
Grade II
Clinical only
Dead
22.4
moderate_burden
RW-KGL-2021-00086
2,021
71
65-74
Male
Other
Sarcoma
Unknown
Microscopy
Dead
33.5
moderate_burden
RW-KGL-2020-00087
2,020
65
65-74
Male
Liver
Squamous cell carcinoma
Grade II
Imaging + clinical
Alive
1.8
moderate_burden
RW-KGL-2018-00088
2,018
29
25-34
Female
Other
Non-keratinizing
Grade II
Clinical only
Alive
16.2
moderate_burden
RW-KGL-2019-00089
2,019
55
55-64
Female
Cervix uteri
Non-keratinizing
Grade IV
Clinical only
Alive
0.4
moderate_burden
RW-KGL-2016-00090
2,016
52
45-54
Female
Cervix uteri
Adenocarcinoma
Grade IV
Imaging + clinical
Dead
53.8
moderate_burden
RW-KGL-2015-00091
2,015
71
65-74
Female
Other
Adenocarcinoma
Grade III
Microscopy
Lost
2.9
moderate_burden
RW-KGL-2019-00092
2,019
82
75+
Female
Cervix uteri
Squamous cell carcinoma
Grade II
Microscopy
Alive
18.6
moderate_burden
RW-KGL-2017-00093
2,017
20
15-24
Female
Breast
Lymphoma
Unknown
Microscopy
Alive
19.6
moderate_burden
RW-KGL-2015-00094
2,015
61
55-64
Female
Breast
Non-keratinizing
Grade III
Imaging + clinical
Dead
6
moderate_burden
RW-KGL-2017-00095
2,017
93
75+
Female
Thyroid
Squamous cell carcinoma
Unknown
Microscopy
Alive
97.5
moderate_burden
RW-KGL-2015-00096
2,015
52
45-54
Female
Cervix uteri
Lymphoma
Grade IV
Clinical only
Alive
25.1
moderate_burden
RW-KGL-2016-00097
2,016
15
15-24
Male
Other
Adenocarcinoma
Unknown
Microscopy
Dead
46.3
moderate_burden
RW-KGL-2016-00098
2,016
12
0-14
Female
Breast
Squamous cell carcinoma
Unknown
Clinical only
Dead
16.5
moderate_burden
RW-KGL-2018-00099
2,018
73
65-74
Female
Cervix uteri
Sarcoma
Grade III
Microscopy
Alive
4.9
moderate_burden
RW-KGL-2015-00100
2,015
31
25-34
Female
Breast
Squamous cell carcinoma
Grade IV
Microscopy
Alive
31.3
moderate_burden
End of preview. Expand in Data Studio

⚠️ Synthetic dataset — Parameterized from published SSA literature, not real observations. Not suitable for empirical analysis or policy inference.

Rwanda Cancer Registry - Kigali

Abstract

This synthetic dataset represents population-based cancer registry data for kigali and is designed to address the significant data gap in cancer research for sub-Saharan Africa. The dataset contains 2,000-3,000 per scenario records per scenario with key epidemiological parameters grounded in GLOBOCAN 2022 estimates, WHO reports, and peer-reviewed literature from the African Cancer Registry Network (AFCRN).

The age-standardized incidence rate (ASIR) of Rwanda Cancer Registry in the target population is approximately 92.0 per 100,000 population (GLOBOCAN 2022). This dataset provides training data for cancer epidemiology modeling, health systems research, and machine learning applications in oncology.

1. Introduction

1.1 Problem Statement

Cancer incidence in sub-Saharan Africa is rising rapidly, with estimated new cases reaching over 1 million annually by 2030. However, the region faces a critical shortage of granular cancer data for research, policy development, and health system planning. Population-based cancer registries cover less than 5% of the African population, creating significant gaps in understanding the true burden of disease.

1.2 Data Gap

  • Limited population-based registry data outside major cities
  • Missing survival and outcome data from most facilities
  • Underrepresentation of pediatric and rare cancers
  • Lack of treatment access and outcome metrics

1.3 Purpose

This dataset supports:

  • Cancer burden estimation and projection modeling
  • Health system capacity planning
  • Machine learning for risk prediction and triage
  • Epidemiological research on cancer patterns
  • Policy development for cancer control programs

2. Methodology

2.1 Target Population

  • Geographic scope: Rwanda
  • Population represented: Urban and rural populations
  • Time period: Variable by data source (2010-2025)

2.2 Variable Selection

Variables were selected based on:

  • IARC/WHO cancer registry standards
  • Data availability in African cancer registries
  • Clinical relevance for cancer control

2.3 Epidemiological Parameterization

All parameters are derived from:

  • GLOBOCAN 2022 (IARC)
  • WHO Cancer Reports
  • African Cancer Registry Network (AFCRN)
  • DHS/MICS survey data
  • Peer-reviewed literature

2.4 Scenario Design

Scenario Description Records
low_burden Low cancer burden setting Varies by dataset
moderate_burden Standard burden setting Varies by dataset
high_burden High burden / late presentation Varies by dataset

2.5 Generation Process

Generation follows a conditional sampling approach based on directed acyclic graphs (DAGs) representing causal relationships between variables:

  1. Sample demographic variables (age, sex, location)
  2. Sample cancer type conditional on demographics
  3. Sample clinical variables (stage, morphology, grade)
  4. Sample treatment and outcome variables
  5. Derive survival times from outcome models

3. Dataset Description

3.1 Key Variables

Population-based cancer registry data for Kigali

3.2 Data Quality

  • All categorical distributions validated against published literature
  • Continuous variables modeled with appropriate statistical distributions
  • Survival times based on exponential models with literature-derived parameters

4. Validation

4.1 Prevalence Verification

All prevalence values are validated against GLOBOCAN 2022 and published registry reports.

4.2 Distribution Quality

  • Age and sex distributions match expected patterns
  • Cancer type frequencies align with regional estimates

4.3 Clinical Plausibility

  • No biologically impossible combinations
  • Treatment patterns consistent with resource-limited settings

5. Usage

5.1 Loading with HuggingFace

from datasets import load_dataset
ds = load_dataset("electricsheepafrica/rwanda-cancer-kigali", "moderate_burden")

5.2 Loading from CSV

import pandas as pd
df = pd.read_csv("rwanda_cancer_kigali_moderate_burden.csv")

6. Limitations

  • Synthetic data: Generated from aggregated statistics, not individual patient records
  • Simplified correlations: May not capture complex dependencies
  • Not for clinical use: Designed for research and ML training only

7. References

  1. GLOBOCAN 2022. IARC Cancer Observatory.
  2. African Cancer Registry Network (AFCRN).
  3. WHO Cancer Control Reports.
  4. DHS/MICS Survey Data.

Citation

@dataset{rwanda_cancer_kigali,
  title={Rwanda Cancer Registry - Kigali},
  author={Electric Sheep Africa},
  year={2025},
  publisher={HuggingFace},
  dataset_url={https://huggingface.co/datasets/electricsheepafrica/rwanda-cancer-kigali}
}

License

CC-BY-4.0

Downloads last month
18